Akorn to Present at the Jefferies 2019 Global Healthcare Conference
May 30 2019 - 7:59AM
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic
pharmaceutical company, today announced that management will
present at the Jefferies 2019 Global Healthcare Conference on
Friday, June 7, 2019 at 9:30 a.m. EDT in New York, NY. A live
webcast of the presentation can be accessed in the investor
relations portion of Akorn's website at
http://investors.akorn.com/events-and-presentations. A replay of
the webcast will be available for 90 days following the conference.
To access the webcast replay, please go to
http://investors.akorn.com/events-and-presentations.
Cautionary Note Regarding Forward-Looking
Statements The webcast may include forward-looking
statements about, among other things, the Company’s business plans
and initiatives, the Company’s commitments to the FDA and
remediation efforts, disruptions during the Standstill Period, the
Company’s anticipated future operating and financial performance,
business plans and prospects, product pipeline, including filings,
approvals and launches, capital allocation, debt refinancing, and
potential dispositions, that are subject to substantial risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. These risk
factors include, but are not limited to: (i) the effect of the
Delaware court’s recent decision against the Company on the
Company’s ability to retain and hire key personnel, its ability to
maintain relationships with its customers, suppliers and others
with whom it does business, or its operating results and business
generally, (ii) the risk that ongoing or future litigation related
to the court’s decision may result in significant costs of defense,
indemnification and/or liability, (iii) the outcome of the
investigation conducted by the Company with the assistance of
outside consultants, into alleged breaches of FDA data integrity
requirements relating to product development at the Company and any
actions taken by the Company, third parties or the FDA as a result
of such investigations, (iv) the difficulty of predicting the
timing or outcome of product development efforts, including FDA and
other regulatory agency approvals and actions, if any, (v) the
timing and success of product launches, (vi) difficulties or delays
in manufacturing, (vii) the Company’s increased indebtedness and
compliance with certain covenants and other obligations under the
Standstill Agreement, which create material uncertainties and risks
to its growth and business outlook, (viii) the Company’s obligation
under the Standstill Agreement to enter into a Comprehensive
Amendment that is satisfactory in form and substance to the
Lenders, (ix) the Company’s obligation under the Standstill
Agreement to pay certain fees and expenses and increased interest
margin, (x) such other risks and uncertainties outlined in the risk
factors detailed in Part I, Item 1A, “Risk Factors,” of the
Company’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2018 (as filed with the Securities and Exchange
Commission (“SEC”) on March 1, 2019), to be detailed in Part II,
Item 1A, “Risk Factors,” of the Company’s Quarterly Report on Form
10-Q for the fiscal quarter ended March 31, 2019 (filed with the
SEC on May 7, 2019) and other risk factors identified from time to
time in the Company’s subsequent reports on Form 8-K and in other
Company filings with the SEC. Readers should carefully review these
risk factors, and should not place undue reliance on the Company’s
forward-looking statements. These forward-looking statements are
based on information, plans and estimates at the date of this
report. The Company undertakes no obligation to update any
forward-looking statements to reflect changes in underlying
assumptions or factors, new information, future events or other
changes. The forward-looking statements in the webcast speak only
as of the original date of the webcast. Akorn assumes no obligation
to update forward-looking statements contained in the webcast as
the result of new information or future events or
developments.
About AkornAkorn, Inc. is a specialty
generic pharmaceutical company engaged in the development,
manufacture and marketing of multisource and branded
pharmaceuticals. Akorn has manufacturing facilities
located in Decatur, Illinois; Somerset, New
Jersey; Amityville, New York;
Hettlingen, Switzerland and Paonta
Sahib, India that manufacture ophthalmic, injectable and
specialty sterile and non-sterile pharmaceuticals. Additional
information is available on Akorn’s website
at www.akorn.com.
Investors/Media:(847)
279-6162Investor.relations@akorn.com
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Apr 2023 to Apr 2024